Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Repotrectinib for treating advanced or metastatic nonsmall-cell lung cancer with ROS1-postive mutation Repotrectinib (TPX 0005) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Resmetirom for non-alcoholic steatohepatitis Resmetirom (MGL-3196) Non-alcoholic steatohepatitis (NASH) Hepatology 2023 View  |  Download
Retifanlimab for advanced/metastatic merkel cell carcinoma Retifanlimab (INCMGA00012; MGA-012) Merkel cell carcinoma (MCC) Skin Cancer 2021 View  |  Download
Retifanlimab for squamous carcinoma of the anal canal – after platinum based chemotherapy Retifanlimab (INCMGA00012; MGA-012) Anal cancer Gastrointestinal Cancer 2020 View  |  Download
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer , Non-small-cell lung cancer (NSCLC) Breast Cancer , Lung and Respiratory Cancer 2024 View  |  Download
Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus REX-001 (Rexmyelocel-T) Critical limb ischaemia (CLI) Cardiovascular System 2017 View  |  Download
Rezafungin for previously untreated invasive candidiasis Rezafungin (CD101) Invasive candidasis Haematology , Infectious Disease 2022 View  |  Download
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2022 View  |  Download
1 2 87 88 89 90 91 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications